Your browser doesn't support javascript.
loading
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
Avula, Vennela; Sharma, Garima; Kosiborod, Mikhail N; Vaduganathan, Muthiah; Neilan, Tomas G; Lopez, Teresa; Dent, Susan; Baldassarre, Lauren; Scherrer-Crosbie, Marielle; Barac, Ana; Liu, Jennifer; Deswal, Anita; Khadke, Sumanth; Yang, Eric H; Ky, Bonnie; Lenihan, Daniel; Nohria, Anju; Dani, Sourbha S; Ganatra, Sarju.
Afiliación
  • Avula V; Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Sharma G; Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri, Kansas City, Missouri, USA.
  • Vaduganathan M; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Neilan TG; Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lopez T; Department of Cardiology, La Paz University Hospital, Madrid, Spain.
  • Dent S; Duke Cancer Institute, Department of Medicine, Duke University, Durham, North Carolina, USA.
  • Baldassarre L; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Scherrer-Crosbie M; Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Barac A; Cardio-Oncology Program, Division of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Liu J; Cardio-Oncology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Deswal A; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Khadke S; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.
  • Yang EH; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Ky B; Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lenihan D; International Cardio-Oncology Society, Tampa, Florida, USA; St. Francis Healthcare, Cape Girardeau, Missouri, USA.
  • Nohria A; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Dani SS; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.
  • Ganatra S; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA. Electronic address: Sarju.Ganatra@lahey.org.
JACC Heart Fail ; 12(1): 67-78, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37897456
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Insuficiencia Cardíaca / Cardiomiopatías / Neoplasias / Antineoplásicos Límite: Adolescent / Adult / Aged / Female / Humans / Male Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Insuficiencia Cardíaca / Cardiomiopatías / Neoplasias / Antineoplásicos Límite: Adolescent / Adult / Aged / Female / Humans / Male Idioma: En Año: 2024 Tipo del documento: Article